Update on morphea: Part II. Outcome measures and treatment

Nicole Fett, Victoria P. Werth

Research output: Contribution to journalReview article

116 Scopus citations

Abstract

Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.

Original languageEnglish (US)
Pages (from-to)231-242
Number of pages12
JournalJournal of the American Academy of Dermatology
Volume64
Issue number2
DOIs
StatePublished - Feb 2011

Keywords

  • autoimmune connective tissue disorder
  • fibrosing disorders
  • localized scleroderma
  • morphea
  • scleroderma
  • systemic sclerosis

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Update on morphea: Part II. Outcome measures and treatment'. Together they form a unique fingerprint.

  • Cite this